Trial Profile
A Phase 2b, Double-Blind, Placebo-Controlled, Exploratory Randomized Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naïve Patients Infected With R5-Tropic HIV-1
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Sep 2022
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary) ; Darunavir; Emtricitabine; Ritonavir; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Pharmacodynamics
- 09 Sep 2022 Results assessing levels of the lysosomal cysteine protease cathepsin B (CatB), and its endogenous inhibitor cystatin B (CysB) were altered in PWH with neurocognitive impairment, and if antiretroviral therapy (ART) further influenced these levels, published in the JAIDS.
- 20 Jun 2016 Results assessing neurocognition published in the AIDS.
- 08 Jun 2016 Results assessing whether maraviroc has differential effects on CD4 count and CD4: CD8 ratio normalization compared to TDF (n = 230) published in the AIDS.